Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
Geoff Block , M.D., director of clinical research atDenver Nephrology Research Glenn Chertow , M.D., professor of medicine (nephrology) atStanford University Lauren Randall Buckley , J.D., group vice president, health policy & reimbursement strategy atJeffrey J. Kimbell & Associates Rory Pace , MPH, RD, CSR, renal dietician, director of nutrition services atSatellite Healthcare
Specific topics that will be addressed include:
- Overview of CKD-MBD and key contributors to the patient population and growth
- Current treatment of hyperphosphatemia and the unmet need from the treating physician's perspective
- Patient management from the community perspective
- Market access and the evolving CKD-MBD reimbursement landscape from the payer perspective
A live webcast of the event will be available on the Events and Presentations page under the investor relations section of
About
Ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. Ardelyx's renal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and submitted a New Drug Application to the U.S. Food and Drug Administration seeking U.S. marketing approval for this indication. To efficiently bring its treatments to market, Ardelyx is pursuing strategic collaborations for tenapanor for IBS-C and hyperphosphatemia in certain territories.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-host-its-first-annual-investor-day-focused-on-treatment-landscape-of-renal-disorders-300724227.html
SOURCE
Chelcie Lister, THRUST Strategic Communications, 910-777-3049, chelcie@thrustsc.com